27.7.2006: Meldung: Millipore Corp.: straight quarter of strong revenue growth in both divisions

Millipore Reports Second Quarter Financial Results
Wednesday July 26, 4:05 pm ET
Company posts fourth straight quarter of strong revenue growth in both divisions continues successful execution of global supply chain initiative

BILLERICA, Mass.----July 26, 2006--Millipore Corporation, a leading provider of products and services that improve productivity in the laboratory and in biopharmaceutical manufacturing, today reported financial results for its second quarter ended July 1, 2006.

Revenues for the second quarter grew 12 percent totaling $273.8 million. Changes in foreign exchange rates during the quarter had no impact on total revenue growth. Millipore"s Bioprocess Division grew 13 percent in the second quarter and its Bioscience Division grew 10 percent. Excluding the impact of acquisitions, revenue growth in the second quarter was 8 percent.

Millipore reported second quarter net income of $29.1 million, or $0.54 per share, compared to net income of $24.0 million or $0.47 per share in the second quarter of 2005. Non-GAAP net income grew approximately 28 percent in the second quarter totaling $38.9 million, or $0.72 per share, compared to non-GAAP net income of $30.3 million, or $0.60 per share in the second quarter of 2005. A reconciliation of GAAP to non-GAAP financial measures is provided in the Company"s financial tables accompanying this press release.

"During the second quarter, our Bioscience Division continued to accelerate its performance due to improved execution and growth in international markets," said Martin Madaus, Chairman & CEO of Millipore. "The momentum of our Bioscience business is complementing the performance of our Bioprocess business, which is delivering solid growth due to the attractive fundamentals of the biopharmaceutical manufacturing market. Over the long-term, this balanced growth profile will help us to generate consistent results and drive higher levels of earnings and cash flow.

"In addition to the strong quarterly performance of both of our divisions, our global supply chain initiatives contributed significantly to the 130 basis points of improvement in our non-GAAP gross profit margins and is ahead of schedule. We closed one facility in the second quarter and have transferred 36 product lines since we began this project. We are now at the mid-point of this program and we anticipate generating higher gross profit margins over the next three years."

Millipore completed its previously announced acquisition of Serologicals Corporation on July 14, 2006, shortly after the close of the second quarter. With the addition of Serologicals" differentiated products, the Company will have a broad portfolio of high-margin consumable products to generate growth in revenues and profitability.

Madaus added, "We are excited about the talent and differentiated product lines we are acquiring from Serologicals. We expect to build on our recent momentum by combining their products with our strong global sales organization. This combination will enable us to increase our market penetration in dynamic segments, such as cell culture supplements, nuclear function, and stem cell research."

Second Quarter Highlights

* Significant growth of the Company"s laboratory water products and services in all geographic regions
* Strong growth in new Bioprocess products, including disposable technologies and virus filters
* Solid, balanced growth in Europe and the Americas
* GAAP earnings per share increase of 14 percent; Non-GAAP earnings per share increase of 20 percent

Quarterly Earnings Call

Millipore will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters at 4:45 p.m. Eastern Time today. The call can be accessed through Millipore"s website: http://www.millipore.com. A replay of the call will be archived on the Investor Relations section of the website and will also be available via telephone by dialing (800) 642-1687 or (706) 645-9291 and entering confirmation code: 3079051. The telephonic replay will be available beginning at 8:00 p.m. ET on July 26, 2006 until 8:00 p.m. ET on July 28, 2006.

About Millipore

Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps to enable pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows by providing reagents, kits and other enabling technologies and products for life science research and development. Millipore has a deep understanding of its customers" research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 Index and employs approximately 5,800 employees in more than 47 facilities worldwide. For additional information on Millipore Corporation, please visit its website at: www.millipore.com.


Joshua Young, 978-715-1527 or 800-225-3384
Director, Investor Relations

Source: Millipore
Aktuell, seriös und kostenlos: Der ECOreporter-Newsletter. Seit 1999.
Nach oben scrollen
ECOreporter Journalistenpreise